IDORSIA LTD

IDORSIA LTD

Share · CH0363463438 · A2DTEB (XSWX)
Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of IDORSIA LTD
No Price
Closing Price XSWX 28.04.2026: 3,90 CHF
29.04.2026 06:03
Current Prices from IDORSIA LTD
ExchangeTickerCurrencyLast TradePriceDaily Change
XHAM: Hamburg
Hamburg
IAGNAS38.HAMB
EUR
29.04.2026 06:03
4,11 EUR
-0,09 EUR
-2,24 %
XDQU: Quotrix
Quotrix
IAGNAS38.DUSD
EUR
29.04.2026 05:27
4,27 EUR
0,07 EUR
+1,76 %
OTC: UTC
UTC
IDRSF
USD
28.04.2026 20:00
4,32 USD
0,00 USD
XSWX: SIX
SIX
IDIA.SW
CHF
28.04.2026 15:03
3,90 CHF
0,16 CHF
+4,28 %
XLON: London
London
0RQE.L
CHF
28.04.2026 15:02
3,91 CHF
0,17 CHF
+4,52 %
XDUS: Düsseldorf
Düsseldorf
IAGNAS38.DUSB
EUR
28.04.2026 14:00
4,34 EUR
0,14 EUR
+3,43 %
Share Float & Liquidity
Free Float 81,80 %
Shares Float 175,69 M
Shares Outstanding 214,78 M
Invested Funds

The following funds have invested in IDORSIA LTD:

Fund
iShares STOXX Europe Small 200 UCITS ETF (DE)
Vol. in million
1.904,03
Percentage (%)
0,30 %
Company Profile for IDORSIA LTD Share
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Company Data

Name IDORSIA LTD
Company Idorsia Ltd
Website https://www.idorsia.com
Primary Exchange XSWX SIX
WKN A2DTEB
ISIN CH0363463438
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Srishti Gupta
Market Capitalization 1 Mrd.
Country Switzerland
Currency CHF
Employees 0,6 T
Address Hegenheimermattweg 91, 4123 Allschwil
IPO Date 2017-06-16
Dividends from 'IDORSIA LTD'
Ex-Date Dividend per Share
16.06.2017 12,00 CHF

Stock Splits

Date Split
14.10.2020 1013:1000
13.10.2020 1013:1000

Ticker Symbols

Name Symbol
Over The Counter IDRSF
Düsseldorf IAGNAS38.DUSB
Frankfurt 19T.F
Hamburg IAGNAS38.HAMB
London 0RQE.L
Quotrix IAGNAS38.DUSD
SIX IDIA.SW
More Shares
Investors who hold IDORSIA LTD also have the following shares in their portfolio:
TELECO ITAL.RISP. ADR/10
TELECO ITAL.RISP. ADR/10 Depository Receipt
WRTS LKD ORDS CUMMINS INDIA 18/06/24
WRTS LKD ORDS CUMMINS INDIA 18/06/24 Verbriefte Derivate